Juvena Therapeutics bags $41 million to accelerate biologics for age-related diseases

Funding will power Juvena’s AI-enabled drug discovery platform to map the therapeutic potential of secreted proteins.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Funding will power Juvena’s AI-enabled drug discovery platform to map the therapeutic potential of secreted proteins.

Juvena Therapeutics, a biotech start-up scaling a computational platform to map the therapeutic potential of secreted proteins, has announced it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2231

Juvena Therapeutics

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Juvena Therapeutics is a clinical-stage biopharmaceutical company developing tissue-restorative biologics derived from stem cell secretomes to address chronic and age-related diseases. The company employs a computationally-driven, AI-enabled platform to systematically identify and engineer secreted proteins with therapeutic potential for muscle regeneration and metabolic disorders. Juvena's pipeline focuses on degenerative diseases with high unmet medical need, including myotonic dystrophy type 1 and metabolic health conditions, positioning the company at the intersection of regenerative medicine and longevity therapeutics.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE